Business Wire

Security Vulnerability Concerns Skyrocket as Neustar’s International Cyber Benchmark Index™ Hits Record High

Del

Neustar®, Inc., a trusted, neutral provider of real-time information services, today released two new cybersecurity reports, reconfirming the need to take action in the face of increasing cyber threats. Both reports, The International Cyber Benchmarks Index and The Changing Face of Cyber Attacks, highlight that IT security professionals are more than twice as worried about data breaches and cyber-attacks today than they were this time last year.

The International Cyber Benchmarks Index is an initiative of the Neustar International Security Council (NISC), an elite group of select cyber security leaders across key industries, that assesses the international cybersecurity landscape from the vantage point of security professionals across the EMEA and U.S. regions. Other key findings from the most recent survey include:

  • Greatest Threats: System compromises and ransomware are the greatest threats to organizations – with 20 percent listing both as their primary concern – closely followed by Distributed Denial of Service (DDoS) attacks (19 percent), financial theft (18 percent), and attacks on intellectual property (17 percent).
  • Increasing Concern: 47 percent of security professionals see DDoS attacks as increasingly harmful to their organization this year, compared to 38 percent last year.
  • No Sign of Slowing Down: 98 percent of companies surveyed have taken steps to minimize risks from the Meltdown-Spectre attack; nine out of ten respondents believe that these attacks will become the norm.
  • Time to Mitigate: In 2017, half of the respondents claimed it would take them between 60 seconds and five minutes to act on an attack, with a quarter claiming it would only take 60 seconds, and the final 25 percent pushing the five-minute mark. Comparing this data to 2018, the clear majority (68 percent) still sit between 60 seconds and five minutes.

These numbers mirror data in Neustar's The Changing Face of Cyber Attacks report, which examined the effects of Memcached attacks and the largest DDoS attack ever recorded at 1.7Tbps. The study demonstrates how the different types of threats propagating today, combined with the sheer volume of attacks, can paint a discouraging picture. Even more alarming, however, is the fact that today’s threats seldom occur in isolation. For example, a DDoS threat in one segment can divert attention from malware in another, while ransomware can be used to hasten data exfiltration. Additional results show:

  • IPv6 attacks will rise as companies adopt the new standard. Neustar thwarted what is believed to be the first IPv6 attack –the attack presented a new direction that attackers are likely to pursue as more and more companies adopt IPv6 and run dual IPv4/IPv6 stacks.
  • IoT growth is paving the way for botnets, which are constantly evolving. Cyber criminals can rent or purchase these botnets with ease – making these threats one of the biggest issues for enterprises today.

Rodney Joffe, Head of NISC and Neustar Senior Vice President and Fellow, said, “While naturally distressing, these results should come as no surprise to anyone. Yes, security professionals are becoming more concerned about the level of threat to their organizations, because that same level of threat is continuing to rise at an extreme rate.”

“As we have seen over the past year, there are more threats to be aware of, whether in the form of DDoS, malware, application layer attacks or something else entirely, leaving professionals confused about where the next attack is coming from.”

“To successfully prepare for a cyber-attack in today’s landscape is to accept that your organization will be the next target. If you are online, you are susceptible to an attack. Whether you are most vulnerable or not is entirely up to you.”

About Neustar, Inc.

Neustar, Inc. is a leading global information services provider driving the connected world forward with responsible identity resolution. As a company built on a foundation of Privacy by Design, Neustar is depended upon by the world’s largest corporations to help grow, guard and guide their businesses with the most complete understanding of how to connect people, places and things. Neustar’s unique, accurate and real-time identity system, continuously corroborated through billions of transactions, empowers critical decisions across our clients’ enterprise needs. More information is available at https://www.home.neustar.

Contact information

Neustar Media Contact
Emma Yousif (Hotwire Global on behalf of Neustar)
neustar@Hotwireglobal.com
+44 (0) 207 608 4645

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Phase 3 Data on Filgotinib in Biologic-Experienced Rheumatoid Arthritis to Be Presented at 2018 ACR/ARHP Annual Meeting20.10.2018 22:30Pressemelding

Gilead Sciences, Inc. (Nasdaq: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced detailed results from the Phase 3 FINCH 2 clinical trial of filgotinib, an investigational, selective JAK1 inhibitor, in adults with moderately-to-severely active rheumatoid arthritis and prior inadequate response or intolerance to biologic agents. The data, which are being presented as a late-breaking poster at the 2018 American College of Rheumatology/Association of Rheumatology Health Professionals (ACR/ARHP) Annual Meeting in Chicago, suggest filgotinib has a potential role in addressing important unmet needs in the treatment of rheumatoid arthritis. Positive efficacy data from FINCH 2 were previously announced in September 2018. The data show statistically significant improvements in the proportion of patients achieving a range of clinical efficacy endpoints, including the proportion of patients achieving American College of Rheumatology 20 percent (ACR20, primary endpoint), 50 percent

Manchester United and True Religion Launch Denim Range19.10.2018 17:37Pressemelding

Manchester United (NYSE:MANU) and luxury denim brand True Religion have collaborated to launch a range of premium club branded denim wear. A first for the club, the new global partnership with the iconic American denim brand will see a range of men’s & women’s co-branded styles go on sale beginning 26th October in the club’s Megastore as well as online via United Direct and truereligion.com & eu.truereligion.com. The exclusive collection features jeans, shirts and jackets, including a highly desirable limited edition denim jacket embroidered with the club’s crest. Fans will have the opportunity to win a selection of clothing from the new range by visiting www.manutd.com/truereligion. Manchester United’s Group Managing Director, Richard Arnold, comments: “True Religion is a well-known, established name in fashion, creating unique designs without compromising on quality. The range we have collaborated on includes the same attention to detail and craftsmanship that has made True Religion

Arch Insurance Announces Strategic Leadership Changes19.10.2018 13:10Pressemelding

Arch Insurance today announced that Matt Shulman will assume the newly created role of CEO, Arch Insurance North America, effective January 1, 2019. In this role, he will lead Arch Insurance’s operations in the United States and Canada. He will report to Nicolas Papadopoulo, Chairman and CEO of Arch Worldwide Insurance Group. Mr. Shulman, who has more than 20 years of experience in the insurance industry, has been with Arch Insurance since 2009 and has served as the President and CEO of Arch Insurance Europe since 2016. “Matt brings significant U.S. and international experience to this role. Under his leadership, together with our senior team, Arch Insurance will continue to enhance our value proposition to our customers through a robust, diversified product portfolio, creative solutions and excellent service,” Mr. Papadopoulo said. Arch Insurance has also created a new organizational structure with three Chief Underwriting Officers (CUO) dedicated to specific lines of business. These

Takeda to Present Results from Phase 3 ALTA-1L Trial Highlighting Intracranial Efficacy of ALUNBRIG® (brigatinib) Versus Crizotinib in First-Line Advanced ALK+ Non-Small Cell Lung Cancer19.10.2018 12:00Pressemelding

Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that intracranial efficacy data from the Phase 3 ALTA-1L (ALK in Lung Cancer Trial of BrigAtinib in 1 st Line) trial showed improved intracranial progression-free survival (PFS) and intracranial objective response rate (ORR) with ALUNBRIG (brigatinib) compared to crizotinib among anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) patients. Data for these secondary endpoints will be presented in a poster discussion at the European Society for Medical Oncology (ESMO) 2018 Congress on Friday, October 19 at 2:00 p.m. CET in Munich, Germany. These results further support ALUNBRIG as a potential treatment for adults with ALK+ locally advanced or metastatic NSCLC who had not received a prior ALK inhibitor. ALUNBRIG is currently not approved as first-line therapy for advanced ALK+ NSCLC. “ALK+ NSCLC often spreads to the brain, so having options that can clearly demonstrate efficacy both in the brain an

Vertex Receives European CHMP Positive Opinion for KALYDECO® (ivacaftor) to Treat Patients With Cystic Fibrosis Aged 12 to <24 months With Certain Mutations in the CFTR Gene19.10.2018 11:54Pressemelding

Vertex Pharmaceuticals (Europe) Limited today announces that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for KALYDECO® (ivacaftor) to include the treatment of people with cystic fibrosis (CF) aged 12 to <24 months who have at least one of the following nine mutations in their cystic fibrosis transmembrane conductance regulator (CFTR) gene: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. If the European Commission issues a favorable adoption of the EMA CHMP opinion for the extension of indication, ivacaftor will be the first and only medicine approved in Europe to treat the underlying cause of CF in patients aged 12 to <24 months, who have specific mutations in the CFTR gene. “Cystic fibrosis is a chronic, progressive disease that is present at birth, with symptoms often occurring in infancy, so early treatment is crucial to deliver the best possible outcomes for patients,” said Reshma Kewalr

Schlumberger Announces Third-Quarter 2018 Results19.10.2018 11:00Pressemelding

Schlumberger Limited (NYSE: SLB) today reported results for the third quarter of 2018. (Stated in millions, except per share amounts) Three Months Ended Change Sept. 30, 2018 Jun. 30, 2018 Sept. 30, 2017 Sequential Year-on-year Revenue $8,504 $8,303 $7,905 2% 8% Pretax operating income $1,152 $1,094 $1,059 5% 9% Pretax operating margin 13.5% 13.2% 13.4% 36 bps 15 bps Net income - GAAP basis $644 $430 $545 50% 18% Net income, excluding charges & credits* $644 $594 $581 8% 11% Diluted EPS - GAAP basis $0.46 $0.31 $0.39 48% 18% Diluted EPS, excluding charges & credits* $0.46 $0.43 $0.42 7% 10% North America revenue $3,189 $3,139 $2,602 2% 23% International revenue $5,215 $5,065 $5,147 3% 1% North America revenue, excluding Cameron $2,572 $2,546 $2,086 1% 23% International revenue, excluding Cameron $4,559 $4,387 $4,430 4% 3% *These are non-GAAP financial measures. See section below entitled "Charges & Credits" for details. Schlumberger Chairman and CEO Paal Kibsgaard commented, “Our third